All In Biotech

Drug Trial Radar · NCT03737253

Hormone Evaluation in Artificial Reproductive Technology

Clinical Study on Pharmacogenetics of Gonadotropin Receptors in Relation to Pregnancy and Life Birth Rate as Well as Unwanted Side Effects Such as Ovarian Hyper Stimulation Syndrome During Assisted Reproduction.

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

810

Actual

Start

Sep 2016

Primary completion

Dec 31, 2021

Study completion Oct 2, 2024

Sponsor

Lead sponsor
Lund UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission
First posted
Nov 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
Female only, from 25 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation. Outcome will be measured as pregnancy success, live born babies and unwanted side effects.

Conditions

  • Female Infertility

Interventions

  • Follitropin alphaDrug

    The objective is to measure the effect of the drug according to gonadotropin receptor genotype.

  • MenotropinDrug

    The objective is to measure the effect of the drug according to gonadotropin receptor genotype.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PregnancyTime frame: up to 12 months after treatment

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Poznan University of Medical Sciences

    Poznan, Poland

  • Reproductive Medicine Center

    Malmö, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.